Study to Validate Methods Assessment of Inflammatory Skin Disease

Overview

About this study

The purpose of this study is to assess the degree of signal alterations or attenuation in formalin-fixed vs. fresh skin biopsy specimens of inflammatory skin disease, using molecular methods .

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Known diagnosis of inflammatory skin disease (e.g., lichen planus);
  • No current systemic immunosuppression therapy;
  • Willingness and ability to participate and consent.

Exclusion Criteria: 

  • Ambiguous diagnosis;
  • Latent disease activity;
  • Insufficient area of uninvolved (control) skin;
  • Relative contraindication to skin biopsy (e.g., serum platelets <10; allergy to lidocaine).

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Julia Lehman, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions